News & Events

2016-12-16
Gradalis to Present at Biotech Showcase

Gradalis to Present at Biotech Showcase™ 2017 Conference

DALLAS, December 15, 2016 – Gradalis, Inc., a clinical-stage biopharmaceutical company focused on developing Vigil® engineered autologous tumor cell (EATC) immunotherapy, will present at the 9th Annual Biotech Showcase to be held January 11, 2017 at the Hilton San Francisco Union Square, San Francisco.  Mr. Sunil Joshi, President and Chief Executive Officer will present an overview of the Company and discuss its clinical development and business strategy at 4:15pm Pacific Time in Room 1.  Mr. Joshi will be available for questions immediately following the presentation.

Members of the investment community, who are interested in meeting with management during the week of January 9 in San Francisco, are encouraged to call Scott Generes at 214-307-8205 to schedule a meeting.

About Gradalis: Gradalis is a fully integrated biotechnology company based in Dallas, Texas that focuses on the development, manufacturing, and commercialization of novel proprietary personalized cellular immunotherapies to treat cancer. Gradalis operates a cGMP manufacturing facility in Carrolton, Texas. For more information about Gradalis, Inc. visit us at www.gradalisinc.com, follow us on //twitter.com/@gradalis_inc">Twitter or on Facebook.

About Vigil EATC: Vigil is an investigational cellular immunotherapy technology that combines the concepts of genetic engineering with the science of immuno-oncology, to enable an immune response to cancer cells. A patient’s tumor cells are engineered with a plasmid carrying the gene vector for shRNA Furin and GMCSF to elicit a systemic T-cell directed immune response when administered to the patient through intradermal injections. By utilizing the patient’s own tumor as the antigen source, Vigil EATC is designed to elicit an immune response that is specifically targeted and broadly relevant to each patient’s unique tumor antigens.  Vigil EATC is being studied in Ewing’s sarcoma and ovarian cancer as a single agent, and in breast cancer, non-small cell lung cancer and melanoma in combination with PD1 and PD-L1 inhibitors.  More information about these studies can be found at www.vigilclinicaltrials.com.

Gradalis® and Vigil® are registered trademarks of Gradalis, Inc.

Contact:

Beth Kriegel

Chief Financial Officer

Gradalis, Inc.

(214) 307-8203